| 摘要 |
Pharmaceutical composition (A) comprises an agent (I) that inhibits the expression or activity of tumor-associated antigens (TAg) that are encoded by particular nucleic acids (NA). Pharmaceutical composition (A) comprises an agent (I) that inhibits the expression or activity of tumor-associated antigens (TAg) that are encoded by particular nucleic acids (NA) which are: (a) any of seq. 13, 1, 5, 9, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105,109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309, 313 or their parts or derivatives; (b) a sequence that hybridizes to (a) under stringent conditions; (c) a degenerate variant of (a) or (b); or (d) a complement of (a)-(c). Independent claims are also included for: (1) pharmaceutical composition (A1) containing a tumor-inhibiting agent (II) that is selective for cells that show (abnormal) expression of TAg; (2) pharmaceutical composition (A2) containing an agent (III) that selectively increases the amount of a complex formed between TAg and an HLA (human lymphocyte antigen) molecule; (3) diagnosing diseases characterized by (abnormal) expression of TAg by detecting at least one of NA, TAg, antibodies specific for TAg, cytotoxic or helper T lymphocytes specific for TAg in a patient sample; (4) detecting regression, progression or outbreak of a disease associated with (abnormal) expression of TAg by monitoring patient samples for at least one of NA, TAg, specific antibodies and/or cytolytic/cytokine-secreting T cells specific for a complex between TAg and MHC (major histocompatibility complex) molecules; (5) NA as defined above as new, including fragments and derivatives; (6) recombinant DNA and RNA that includes NA of (5); (7) host cell containing the NA of (5) or recombinant DNA of (6); (8) protein or polypeptide (Z) encoded by NA, having any of seq. n+1 where n = any seq. number for NA listed above, and their immunogenic fragments; (9) agents (X) that bind specifically to (Z); (10) antibodies (Ab) that bind selectively to a complex formed from (Z) and an MHC molecule, but not to either of the complex components alone; (11) conjugate between (X) or Ab and a therapeutic or diagnostic agent; (12) kit for detecting (abnormal) expression of TAg; (13) recombinant DNA comprising a promoter region and any of the specified NA sequences; and (14) antibodies that bind to an extracellular region of proteins seq. n+1. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of specific antigens. |
